ERBB2 and breast carcinoma: An alternative strategy was also based on the transmembrane domain of platelet-derived growth factor receptor (PDGFR) to express a CD3/HER2 bi-specific fusion protein for an EV-mediated T cell-killing activity in HER2-positive breast cancer cells [23].